Kenya Kamimura
Overview
Explore the profile of Kenya Kamimura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
1082
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kanda T, Sasaki-Tanaka R, Kimura N, Abe H, Yoshida T, Hayashi K, et al.
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076514
Patients with chronic cholestatic liver diseases often experience itch and struggle with this symptom. We discuss the mechanism of itch in patients with chronic cholestatic liver diseases, such as primary...
2.
Ishikawa N, Watanabe Y, Maeda Y, Yoshida T, Kimura N, Abe H, et al.
Regen Ther
. 2025 Feb;
28:509-516.
PMID: 39991509
Introduction: Cirrhosis is a disease with poor prognosis that requires the development of a novel therapeutic approach alternative to liver transplantation. In this study, we focused on the placenta and...
3.
Yakubo S, Abe H, Li Y, Kudo M, Kimura A, Wakabayashi T, et al.
Diseases
. 2024 Dec;
12(12.
PMID: 39727647
Metabolic dysfunction-associated steatotic liver disease (MASLD) causes cellular senescence due to oxidative stress, endoplasmic reticulum stress, and ectopic fat deposition in the liver. Recently, dasatinib, an antitumor agent, and quercetin,...
4.
Maeda Y, Watanabe Y, Ishikawa N, Yoshida T, Kimura N, Abe H, et al.
Regen Ther
. 2024 Nov;
26:1048-1057.
PMID: 39569343
Introduction: Cirrhosis remains a significant clinical challenge due to its poor prognosis and limited treatment options, creating a high unmet medical need for the development of novel therapies. In this...
5.
Ogawa K, Kamimura K, Ishii S, Endo S, Ishikawa N, Abe H, et al.
Nihon Shokakibyo Gakkai Zasshi
. 2024 Sep;
121(9):769-776.
PMID: 39261058
Herein, we report a case of a man with a large symptomatic hepatic cyst that gradually enlarged over a follow-up period of 15 years, which eventually caused epigastric fullness and...
6.
Koyama K, Sakamaki A, Morita S, Nagayama I, Kudo M, Tanaka Y, et al.
Sci Rep
. 2024 Sep;
14(1):21126.
PMID: 39256539
The onset and progression mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are being studied. We developed and analyzed a new mouse model of obesity...
7.
Hsiao Y, Yoshida Y, Okuda S, Abe M, Mizuno S, Takahashi S, et al.
EMBO J
. 2024 Aug;
43(21):4846-4869.
PMID: 39160276
Metabolic dysfunction-associated steatohepatitis (MASH, previously termed non-alcoholic steatohepatitis (NASH)), is a major complication of obesity that promotes fatty liver disease. MASH is characterized by progressive tissue fibrosis and sterile liver...
8.
Tominaga K, Kojima Y, Kawata Y, Takahashi K, Sato H, Tsuchiya A, et al.
Biosci Microbiota Food Health
. 2024 Jul;
43(3):162-169.
PMID: 38966047
Diversion colitis (DC) is characterized by mucosal inflammation in the defunctioned segment of the colon following a colostomy or ileostomy. The major causes of DC are an increase in the...
9.
Nagayama I, Kamimura K, Owaki T, Ko M, Nagoya T, Tanaka Y, et al.
Hepatol Int
. 2024 Mar;
18(3):1067-1069.
PMID: 38451408
No abstract available.
10.
Ko M, Kamimura K, Owaki T, Nagoya T, Sakai N, Nagayama I, et al.
Dis Model Mech
. 2023 Nov;
16(12).
PMID: 38032301
No abstract available.